1
|
Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, Ohrndorf S, Pfeiffenberger M, Röhner E, Matziolis G, Burmester GR, Buttgereit F, Hoff P. CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. Int J Mol Sci 2018; 19:ijms19082312. [PMID: 30087255 PMCID: PMC6121442 DOI: 10.3390/ijms19082312] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 08/01/2018] [Accepted: 08/02/2018] [Indexed: 02/07/2023] Open
Abstract
Mesenchymal stem/stromal cells (MSCs) are stem cells of the connective tissue, possess a plastic phenotype, and are able to differentiate into various tissues. Besides their role in tissue regeneration, MSCs perform additional functions as a modulator or inhibitor of immune responses. Due to their pleiotropic function, MSCs have also gained therapeutic importance for the treatment of autoimmune diseases and for improving fracture healing and cartilage regeneration. However, the therapeutic/immunomodulatory mode of action of MSCs is largely unknown. Here, we describe that MSCs express the inhibitory receptor CTLA-4 (cytotoxic T lymphocyte antigen 4). We show that depending on the environmental conditions, MSCs express different isoforms of CTLA-4 with the secreted isoform (sCTLA-4) being the most abundant under hypoxic conditions. Furthermore, we demonstrate that the immunosuppressive function of MSCs is mediated mainly by the secretion of CTLA-4. These findings open new ways for treatment when tissue regeneration/fracture healing is difficult.
Collapse
Affiliation(s)
- Timo Gaber
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Kerstin Schönbeck
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Holger Hoff
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Cam Loan Tran
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Cindy Strehl
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Annemarie Lang
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Sarah Ohrndorf
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
| | - Moritz Pfeiffenberger
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Eric Röhner
- Department of Orthopedics, Campus Eisenberg, Jena University Hospital, Klosterlausnitzer Straße 81, 07607 Eisenberg, Germany.
| | - Georg Matziolis
- Department of Orthopedics, Campus Eisenberg, Jena University Hospital, Klosterlausnitzer Straße 81, 07607 Eisenberg, Germany.
| | - Gerd-R Burmester
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Frank Buttgereit
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
| | - Paula Hoff
- Department of Rheumatology and Clinical Immunology, Charité⁻Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
- German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany.
- Department of Orthopedics, Campus Eisenberg, Jena University Hospital, Klosterlausnitzer Straße 81, 07607 Eisenberg, Germany.
- Endokrinologikum Berlin, 10117 Berlin, Germany.
| |
Collapse
|
2
|
Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 2017; 8:6730-6741. [PMID: 28036269 PMCID: PMC5351666 DOI: 10.18632/oncotarget.14268] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Accepted: 11/30/2016] [Indexed: 01/18/2023] Open
Abstract
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that promotes G2/M-phase transition, is expressed in elevated levels in high-risk neuroblastomas and correlates with unfavorable patient outcome. Recently, we and others have presented PLK1 as a potential drug target for neuroblastoma, and reported that the BI2536 PLK1 inhibitor showed antitumoral actvity in preclinical neuroblastoma models. Here we analyzed the effects of GSK461364, a competitive inhibitor for ATP binding to PLK1, on typical tumorigenic properties of preclinical in vitro and in vivo neuroblastoma models. GSK461364 treatment of neuroblastoma cell lines reduced cell viability and proliferative capacity, caused cell cycle arrest and massively induced apoptosis. These phenotypic consequences were induced by treatment in the low-dose nanomolar range, and were independent of MYCN copy number status. GSK461364 treatment strongly delayed established xenograft tumor growth in nude mice, and significantly increased survival time in the treatment group. These preclinical findings indicate PLK1 inhibitors may be effective for patients with high-risk or relapsed neuroblastomas with upregulated PLK1 and might be considered for entry into early phase clinical trials in pediatric patients.
Collapse
Affiliation(s)
- Kristian W Pajtler
- Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University, Jeonju, Republic of Korea
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital, Heidelberg, Germany
- German Cancer Consortium (DKTK Core Center Heidelberg), Germany
| | - Natalie Sadowski
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Sandra Ackermann
- Department of Pediatric Oncology and Hematology, University Children's Hospital, and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - Kristina Althoff
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Kerstin Schönbeck
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
| | - Katharina Batzke
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Simon Schäfers
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Andrea Odersky
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Lukas Heukamp
- NEO New Oncology, Cologne, Germany
- Institute for Hematopathology, Hamburg, Germany
| | - Kathy Astrahantseff
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
| | - Annette Künkele
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
| | - Hedwig E Deubzer
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
| | - Alexander Schramm
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Annika Sprüssel
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
- Berlin Institute of Health (BIH), Germany
- German Cancer Consortium (DKTK Berlin), Germany
| | - Theresa Thor
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
- German Cancer Consortium (DKTK Essen), Germany
- Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Sven Lindner
- Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany
| | - Angelika Eggert
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
- Berlin Institute of Health (BIH), Germany
- German Cancer Consortium (DKTK Berlin), Germany
| | - Matthias Fischer
- Department of Pediatric Oncology and Hematology, University Children's Hospital, and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
- Medical Faculty, University of Cologne, Cologne, Germany
| | - Johannes H Schulte
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany
- Berlin Institute of Health (BIH), Germany
- German Cancer Consortium (DKTK Berlin), Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
3
|
Schönbeck K, Tran C, Strehl C, Gaber T, Jakstadt M, Röhner E, Burmester G, Buttgereit F, Hoff P. SAT0564 Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Expressed in Human Mesenchymal Stromal Cells. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Wagegg M, Gaber T, Lohanatha FL, Hahne M, Strehl C, Fangradt M, Tran CL, Schönbeck K, Hoff P, Ode A, Perka C, Duda GN, Buttgereit F. Hypoxia promotes osteogenesis but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1 dependent manner. PLoS One 2012; 7:e46483. [PMID: 23029528 PMCID: PMC3459928 DOI: 10.1371/journal.pone.0046483] [Citation(s) in RCA: 140] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Accepted: 08/31/2012] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Bone fracture initiates a series of cellular and molecular events including the expression of hypoxia-inducible factor (HIF)-1. HIF-1 is known to facilitate recruitment and differentiation of multipotent human mesenchymal stromal cells (hMSC). Therefore, we analyzed the impact of hypoxia and HIF-1 on the competitive differentiation potential of hMSCs towards adipogenic and osteogenic lineages. METHODOLOGY/PRINCIPAL FINDINGS Bone marrow derived primary hMSCs cultured for 2 weeks either under normoxic (app. 18% O(2)) or hypoxic (less than 2% O(2)) conditions were analyzed for the expression of MSC surface markers and for expression of the genes HIF1A, VEGFA, LDHA, PGK1, and GLUT1. Using conditioned medium, adipogenic or osteogenic differentiation as verified by Oil-Red-O or von-Kossa staining was induced in hMSCs under either normoxic or hypoxic conditions. The expression of HIF1A and VEGFA was measured by qPCR. A knockdown of HIF-1α by lentiviral transduction was performed, and the ability of the transduced hMSCs to differentiate into adipogenic and osteogenic lineages was analyzed. Hypoxia induced HIF-1α and HIF-1 target gene expression, but did not alter MSC phenotype or surface marker expression. Hypoxia (i) suppressed adipogenesis and associated HIF1A and PPARG gene expression in hMSCs and (ii) enhanced osteogenesis and associated HIF1A and RUNX2 gene expression. shRNA-mediated knockdown of HIF-1α enhanced adipogenesis under both normoxia and hypoxia, and suppressed hypoxia-induced osteogenesis. CONCLUSIONS/SIGNIFICANCE Hypoxia promotes osteogenesis but suppresses adipogenesis of human MSCs in a competitive and HIF-1-dependent manner. We therefore conclude that the effects of hypoxia are crucial for effective bone healing, which may potentially lead to the development of novel therapeutic approaches.
Collapse
Affiliation(s)
- Markus Wagegg
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
| | - Timo Gaber
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
- * E-mail:
| | - Ferenz L. Lohanatha
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
| | - Martin Hahne
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
- Berlin-Brandenburg School of Regenerative Therapies, Charité University Hospital, Berlin, Germany
| | - Cindy Strehl
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
| | - Monique Fangradt
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
| | - Cam Loan Tran
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
| | - Kerstin Schönbeck
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
| | - Paula Hoff
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
| | - Andrea Ode
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
- Julius Wolff Institute and Center for Musculoskeletal Surgery, Charité University Hospital, Berlin, Germany
| | - Carsten Perka
- Orthopaedic Departments, Charité University Hospital, Berlin, Germany
| | - Georg N. Duda
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
- Julius Wolff Institute and Center for Musculoskeletal Surgery, Charité University Hospital, Berlin, Germany
| | - Frank Buttgereit
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
- German Arthritis Research Center, Berlin, Germany
- Berlin-Brandenburg Center of Regenerative Therapies, Charité University Hospital, Berlin, Germany
| |
Collapse
|